EIF4G1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL46211	0.75	1/20
SCHEMBL18301010	0.75	1/20
SCHEMBL23145046	0.75	1/20
SCHEMBL3892300	0.74	1/20
SCHEMBL3892304	0.74	1/20
SCHEMBL4398637	0.72	1/20
SCHEMBL4402019	0.72	1/20
SCHEMBL3132319	0.72	1/20
SCHEMBL3132328	0.72	1/20
SCHEMBL3132334	0.72	1/20
SCHEMBL8594643	0.71	1/20
SCHEMBL8594645	0.71	1/20
SCHEMBL46215	0.71	1/20
SCHEMBL16639749	0.71	1/20
SCHEMBL20339627	0.71	1/20
SCHEMBL20339629	0.71	1/20
SCHEMBL20339745	0.70	1/20
SCHEMBL20339746	0.70	1/20
SCHEMBL20339291	0.69	1/20
SCHEMBL20339295	0.69	1/20

Clinical trials — most relevant to EIF4G1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.	PHASE1/PHASE2	RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
MEHMO Natural History and Biomarkers	nan	RECRUITING
Autophagy Bladder Cancer	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma	nan	RECRUITING
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes	nan	COMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation	nan	COMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN
Genomic Translation for Amyotrophic Lateral Sclerosis Care	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF4G1 binder may also engage these)

Protein	Name	Similarity
Q6NZJ6	—	1.000	Q6NZJ6 →
O43432	—	0.997	O43432 →
Q8IZ21	—	0.995	Q8IZ21 →
P53814	—	0.994	P53814 →
Q80XI3	—	0.994	Q80XI3 →
Q8K0V4	—	0.994	Q8K0V4 →
Q7TN02	—	0.994	Q7TN02 →
Q9DB00	—	0.994	Q9DB00 →
Q2EJA0	—	0.993	Q2EJA0 →
A0A0R4IZ84	—	0.993	A0A0R4IZ84 →
Q5XHF3	—	0.993	Q5XHF3 →
Q9R0A0	—	0.993	Q9R0A0 →
Q9ULH7	—	0.993	Q9ULH7 →
Q9H329	—	0.993	Q9H329 →
Q9H4Z2	—	0.993	Q9H4Z2 →
Q5HZJ0	—	0.992	Q5HZJ0 →
P41110	—	0.992	P41110 →
Q90YL3	—	0.992	Q90YL3 →
LARP1	La-related protein 1	0.992	landscape →
AAK1	AP2-associated protein kinase 1	0.992	landscape →
Q8BGT6	—	0.992	Q8BGT6 →
Q5CZI8	—	0.992	Q5CZI8 →
Q5RAU1	—	0.992	Q5RAU1 →
Q80Y56	—	0.992	Q80Y56 →
Q5TM26	—	0.992	Q5TM26 →
Q6IRR0	—	0.991	Q6IRR0 →
Q9Z1N7	—	0.991	Q9Z1N7 →
Q9JLV1	—	0.991	Q9JLV1 →
Q9Y2H5	—	0.991	Q9Y2H5 →
O60237	—	0.991	O60237 →